Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$3000.0.

  • Inhibrx Biosciences' Change in Receivables rose 9960.94% to -$3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $728000.0, marking a year-over-year increase of 293333.33%. This contributed to the annual value of -$381000.0 for FY2024, which is 17121.5% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Change in Receivables stood at -$3000.0 for Q3 2025, which was up 9960.94% from $872000.0 recorded in Q2 2025.
  • Inhibrx Biosciences' Change in Receivables' 5-year high stood at $872000.0 during Q2 2025, with a 5-year trough of -$768000.0 in Q3 2024.
  • Its 3-year average for Change in Receivables is $84000.0, with a median of $4000.0 in 2023.
  • Per our database at Business Quant, Inhibrx Biosciences' Change in Receivables tumbled by 1930000.0% in 2024 and then skyrocketed by 42905.66% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Change in Receivables (Quarter) stood at $447000.0 in 2023, then crashed by 90.6% to $42000.0 in 2024, then plummeted by 107.14% to -$3000.0 in 2025.
  • Its Change in Receivables stands at -$3000.0 for Q3 2025, versus $872000.0 for Q2 2025 and -$183000.0 for Q1 2025.